NCT04572256 MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
| NCT ID | NCT04572256 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Austin V Stone |
| Condition | ACL Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2021-02-01 |
| Primary Completion | 2027-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Eligibility Criteria
Inclusion Criteria: 1. Undergoing primary ACL reconstruction 2. Age between 25-50 3. Concomitant meniscus injury Exclusion Criteria: 1. Undergoing revision procedures 2. Multiple ligament injuries requiring multiple ligament reconstruction/repair 3. Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score \>= 15) 4. Found to not have a meniscus tear at the time of surgery